Veterans with prostate cancer treated at facilities run by the United States Department of Veterans Affairs (VA) may be scientifically underserved in clinical trial access, according to recent research revealing that veterans only have access to 6% of prostate cancer clinical trials. Madison Krischak, MD, University of Michigan, Ann Arbor, presented the data at the 25th Annual Meeting of the Society of Urologic Oncology. Dr. Krischak and colleagues used ClinicalTrials.gov to identify phase 2-3 prostate cancer trials after January 1, 2007, and the VA directory was accessed for the total number of VA hospitals. ...
Disparities in Prostate Cancer
Advertisement
Prostate-specific antigen (PSA) velocity and PSA values taken together may improve the specificity of monitoring.
Patients and survivors who engaged in physical activity experienced a protective effect on mental health.
Contaminants, such as heavy metals, pesticides, and microbial pathogens, may influence cancer severity.
Patients and caregivers most valued the role of genetics in understanding risk stratification.
The rate of prostate cancer mortality is higher in parts of the United States where structural racism is also higher.
The slower recovery PSA screening rate in Black men highlights the persistent racial disparities in health care access.
In this analysis, the model performed best for predicting survival Asian patients and worst for Non-Hispanic Black patients.
Hispanic men who are Black or Cuban had the lowest rates of prostate-specific antigen screening.
Advertisement
Expert Interviews
Dr. Von Nguyen, Chief Clinical Officer at Evolent, discusses the use of AI and technology in medicine and population health.
Drs. Julia Schulz and Michael Dovidio discuss lab values to determine GLP-1 drug coverage and improve prescription access.
Dr. Kamal Golla of Evolent discusses specialist engagement with primary care physicians for high-quality patient care.
Patient advocate and influencer Alisha Bridges talks about living with Plaque & Scalp Psoriasis as a person of color.
Dr. Luke Twelves, VP of Medical for Lindus Health discusses the lack of diversity in type 2 diabetes clinical trials.
Dr. Amy McMichael discusses plaque psoriasis on skin of color and Johnson & Johnson's VISIBLE study.
Urban Health Today reports on clinical news and policy updates that directly impact urban health care providers and their patients.
Get research and expert insights straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.